The Art of Seeing Around Corners: James Richman’s Predictions for the Next Decade of Medtech
James Richman, the investor-turned-CEO known for his...
23andMe Bankruptcy Shakes Biotech Sector as Early Warning Signs Go Unheeded
The recent bankruptcy filing of 23andMe has sent ripples...
Biotech Private Equity and Investment Trends for 2024
The past few years have seen a boom in venture capital...